What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The FDA ended the legal authorization for mass compounding of GLP-1 medications (specifically semaglutide and tirzepatide) in May 2025 because the national shortage of FDA-approved versions of these drugs was resolved, and the agency tightened oversight to prevent unapproved "copy" drugs from entering the supply chain [1][2].

Who is still operating legally? Only legitimate, licensed pharmacies and outsourcing facilities that meet specific, narrow exemptions under the FDA’s Drug Supply Chain Security Act and Section 503A/503B of the FD&C Act are operating legally. Specifically, legal operation requires:

1. No Routine Copying: They cannot routinely compound drugs that are "essentially copies" of commercially available FDA-approved versions (e.g., standard Ozempic, Wegovy, Mounjaro, or Zepbound) [2][3].
2. Specific Patient Needs: Compounding is only permitted if a treating physician documents a bona fide medical need that cannot be met by an FDA-approved drug (e.g., a non-standard dose or unique formulation not commercially available) [1][2].
3. Low Volume Restriction: The FDA may not take action against compounders filling four or fewer prescriptions of an "essentially copy" drug per calendar month, but this is a limited enforcement discretion, not a broad authorization for mass production [3].

Brands and Services to Avoid: Do not use telehealth companies or online pharmacies that advertise "compounded GLP-1s" for weight loss without a documented medical need for a unique formulation, as the FDA has issued 30 warning letters to such telehealth firms for illegal marketing and false claims [7][8]. These companies often sell unapproved versions that may contain fraudulent ingredients or incorrect dosages, leading to over 990 reported adverse events for compounded semaglutide and 730 for compounded tirzepatide [4].

Recommended Legal Alternatives: To obtain GLP-1s legally and safely, patients should consult a licensed healthcare provider for FDA-approved brands such as:

• Wegovy or Ozempic (semaglutide)
• Zepbound or Mounjaro (tirzepatide)

These are available through standard pharmacies once the shortage officially ended, providing regulated safety, effectiveness, and quality assurance that compounded versions lack [2][5].